- Home
- JWEL vs TCRT Comparison
JWEL vs TCRT Comparison
Compare JWEL & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- TCRT
- Stock Information
- Founded
- JWEL 2012
- TCRT 1998
- Country
- JWEL China
- TCRT United States
- Employees
- JWEL N/A
- TCRT N/A
- Industry
- JWEL Other Consumer Services
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- TCRT Health Care
- Exchange
- JWEL Nasdaq
- TCRT Nasdaq
- Market Cap
- JWEL 3.8M
- TCRT 3.8M
- IPO Year
- JWEL 2021
- TCRT N/A
- Fundamental
- Price
- JWEL $1.98
- TCRT $2.70
- Analyst Decision
- JWEL
- TCRT
- Analyst Count
- JWEL 0
- TCRT 0
- Target Price
- JWEL N/A
- TCRT N/A
- AVG Volume (30 Days)
- JWEL 8.2K
- TCRT 14.4K
- Earning Date
- JWEL 06-10-2025
- TCRT 05-15-2025
- Dividend Yield
- JWEL N/A
- TCRT N/A
- EPS Growth
- JWEL N/A
- TCRT N/A
- EPS
- JWEL N/A
- TCRT N/A
- Revenue
- JWEL $132,981,531.00
- TCRT $11,000.00
- Revenue This Year
- JWEL N/A
- TCRT $5,680,500.00
- Revenue Next Year
- JWEL N/A
- TCRT N/A
- P/E Ratio
- JWEL N/A
- TCRT N/A
- Revenue Growth
- JWEL N/A
- TCRT 83.33
- 52 Week Low
- JWEL $1.06
- TCRT $1.31
- 52 Week High
- JWEL $3.71
- TCRT $11.30
- Technical
- Relative Strength Index (RSI)
- JWEL 47.86
- TCRT 52.57
- Support Level
- JWEL $1.90
- TCRT $2.50
- Resistance Level
- JWEL $2.18
- TCRT $2.95
- Average True Range (ATR)
- JWEL 0.13
- TCRT 0.17
- MACD
- JWEL -0.02
- TCRT -0.04
- Stochastic Oscillator
- JWEL 24.34
- TCRT 50.00
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.